Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EPC stock price vs LLY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LLY's multiple
Needs LLY P/E.
Implied fair value · at EPC's multiple
Needs EPC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EDGEWELL PERSONAL CARE COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
EPC vs PG
COLGATE PALMOLIVE CO
EPC vs CL
CHURCH & DWIGHT CO INC /DE/
EPC vs CHD
COTY INC.
EPC vs COTY
Pfizer Inc.
EPC vs PFE
Merck & Co., Inc.
EPC vs MRK
Johnson & Johnson
EPC vs JNJ
AbbVie Inc.
EPC vs ABBV
Amgen Inc.
EPC vs AMGN
Bristol-Myers Squibb Company
EPC vs BMY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EPC can stabilize revenue and expand margins without worsening leverage, then holding or selectively buying makes sense because the stock already trades near the low end of its valuation framework; otherwise, the weak growth, low profitability, and 5.0x net debt/EBITDA argue for caution.
EPC’s implied price of $27.38 sits 3.5% below the current price of $28.38, so the stock is only modestly above the P/E-based estimate. The much lower trading multiples versus LLY reflect a structurally weaker operating profile rather than a clear mispricing.
Supporting Metrics
